Para-aminohippuric Acid
Phase 1Small molecule
Para-aminohippuric Acid is one of 36 small molecule programs targeting Hypertension. It is currently in Phase 1.
2
Indications
4
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
161 competitors in Hypertension
#DrugCompanyPhaseTrials
1Nitrostat
VViatris Specialty LLC
Phase 3
Baxfendy
AstraZenecaPhase 3
Alka-Seltzer
AAbbott
Phase 3
SGLT2
PProf. Dr. med. Ingo Eitel
Phase 3
Avastin
RochePreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Nipride
EExela Pharma Sciences, LLC.
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Vascular Dysfunction2 trials
Vascular Dysfunction in Diabetes: Genes and Hormones
Terminated·—··NCT01511042·100 enrolled
Caveolin-1 and Vascular Dysfunction
Active, not recruiting·—·Phase 1·NCT01426529·120 enrolled
Hypertension1 trial
Genetic Mechanisms in Human Hypertension
Terminated·—··NCT01456208·150 enrolled
Unspecified1 trial
Evaluation of Lysine-Specific Demethylase 1
Withdrawn·—·N/A·NCT01702688
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Para-aminohippuric Acid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- BBrigham and Women's Hospital